Novel platinum chemotherapy in development with promising preclinical results

Researchers from the University of Texas, the MD Anderson Cancer Center and biotech firm OncoTEX (TX, USA) have developed a promising two-part drug candidate for platinum-based chemotherapy. The candidate shows reduced toxicity to healthy cells and an increased ability to avoid typical resistance mechanisms.Platinum-based chemotherapy is a mainstay of cancer care, yet it is often fraught with severe toxicity and the development of resistance to the treatment. Researchers from the University of Texas and Austin-based Biotech firm, OncoTEX, have recently reported results suggesting the development of a viable alternative to these treatments. The study, published in Proceedings of the National...